William Pearce1, Jason Hsu, Steven Yeh. 1. aEmory Eye Center, Emory University School of Medicine, Atlanta, Georgia bRetina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: Emerging developments and research for drug delivery to the posterior segment offer a promising future for the treatment of vitreoretinal disease. As new technologies enter the market, clinicians should be aware of new indications and ongoing clinical trials. RECENT FINDINGS: This review summarizes the advantages and shortcomings of the most commonly used drug delivery methods, including vitreous dynamics, physician sustainability and patient preferences. Currently available, intravitreal, corticosteroid-release devices offer surgical and in-office management of retinal vascular disease and posterior uveitis. The suprachoroidal space offers a new anatomic location for the delivery of lower dose medications directly to the target tissue. Implantable drug reservoirs would potentially allow for less frequent intravitreal injections reducing treatment burdens and associated risks. Newer innovations in encapsulated cell technology offer promising results in early clinical trials. SUMMARY: Although pars plana intravitreal injection remains the mainstay of therapy for many vitreoretinal diseases, targeted delivery and implantable eluting devices are rapidly demonstrating safety and efficacy. These therapeutic modalities offer promising options for the vitreoretinal therapeutic landscape.
PURPOSE OF REVIEW: Emerging developments and research for drug delivery to the posterior segment offer a promising future for the treatment of vitreoretinal disease. As new technologies enter the market, clinicians should be aware of new indications and ongoing clinical trials. RECENT FINDINGS: This review summarizes the advantages and shortcomings of the most commonly used drug delivery methods, including vitreous dynamics, physician sustainability and patient preferences. Currently available, intravitreal, corticosteroid-release devices offer surgical and in-office management of retinal vascular disease and posterior uveitis. The suprachoroidal space offers a new anatomic location for the delivery of lower dose medications directly to the target tissue. Implantable drug reservoirs would potentially allow for less frequent intravitreal injections reducing treatment burdens and associated risks. Newer innovations in encapsulated cell technology offer promising results in early clinical trials. SUMMARY: Although pars plana intravitreal injection remains the mainstay of therapy for many vitreoretinal diseases, targeted delivery and implantable eluting devices are rapidly demonstrating safety and efficacy. These therapeutic modalities offer promising options for the vitreoretinal therapeutic landscape.
Authors: Samirkumar R Patel; Damian E Berezovsky; Bernard E McCarey; Vladimir Zarnitsyn; Henry F Edelhauser; Mark R Prausnitz Journal: Invest Ophthalmol Vis Sci Date: 2012-07-01 Impact factor: 4.799
Authors: Timothy W Olsen; Xiao Feng; Kathy Wabner; Karl Csaky; Stefan Pambuccian; J Douglas Cameron Journal: Invest Ophthalmol Vis Sci Date: 2011-07-01 Impact factor: 4.799
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li Journal: Ophthalmology Date: 2011-07-20 Impact factor: 12.079
Authors: Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio Journal: Ophthalmology Date: 2011-06-29 Impact factor: 12.079
Authors: Peter A Campochiaro; Quan Dong Nguyen; Gulnar Hafiz; Steven Bloom; David M Brown; Miguel Busquets; Thomas Ciulla; Leonard Feiner; Nelson Sabates; Kathleen Billman; Barry Kapik; Ken Green; Frances E Kane Journal: Ophthalmology Date: 2012-12-04 Impact factor: 12.079
Authors: Rahul N Khurana; Suri N Appa; Colin A McCannel; Michael J Elman; Susan E Wittenberg; David J Parks; Saad Ahmad; Steven Yeh Journal: Ophthalmology Date: 2013-07-24 Impact factor: 12.079
Authors: Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth Journal: Ophthalmology Date: 2012-10-17 Impact factor: 12.079
Authors: Muhammad Faris Adrianto; Febri Annuryanti; Clive G Wilson; Ravi Sheshala; Raghu Raj Singh Thakur Journal: Drug Deliv Transl Res Date: 2021-08-11 Impact factor: 5.671
Authors: Sahar Awwad; Abeer H A Mohamed Ahmed; Garima Sharma; Jacob S Heng; Peng T Khaw; Steve Brocchini; Alastair Lockwood Journal: Br J Pharmacol Date: 2017-10-10 Impact factor: 8.739
Authors: Ahmed B Sallam; Kyle A Kirkland; Richard Barry; Mohamed Kamel Soliman; Tayyeba K Ali; Sue Lightman Journal: Med Hypothesis Discov Innov Ophthalmol Date: 2018
Authors: Nahla Jemni-Damer; Atocha Guedan-Duran; María Fuentes-Andion; Nora Serrano-Bengoechea; Nuria Alfageme-Lopez; Félix Armada-Maresca; Gustavo V Guinea; José Perez-Rigueiro; Francisco Rojo; Daniel Gonzalez-Nieto; David L Kaplan; Fivos Panetsos Journal: Front Bioeng Biotechnol Date: 2020-12-10
Authors: João Heitor Marques; Ana Carolina Abreu; Nisa Silva; Angelina Meireles; Bernardete Pessoa; João Melo Beirão Journal: Int Med Case Rep J Date: 2021-02-26